Kush M Parmar is a high-level expert, that works in Immuneel Therapeutics as a Co-Founder since 2019. Kush M Parmar has earned professional experience in more than 19 positions at various companies. Kush M Parmar went to the Harvard Business School and was studying there from 2010 to 2010. Boston, Massachusetts is the city, where this person was lastly known to settle. Kush's email address and number can be accessed through this website on demand.
Name variants:
Kush Parmar
Last updated May 30, 2024
Contact Information
Last Update
Jul 3, 2022
Email
ku**@5amventures.com, ku**@post.harvard.edu
Location
Boston, MA
Company
Immuneel Therapeutics
Workplace
Co-Founder
Work History
Co-Founder
Mission-driven enterprise to spearhead access to cell and gene therapies for cancer patients in India. Co-founded by Kiran Mazumdar Shaw, Kush Parmar and Siddhartha Mukherjee. Headquartered ...
from Jul 2019
Chairman
215 1St St SUITE 430, Cambridge, MA 02142
Vor Biopharma is an immuno-oncology company developing novel therapies with broad potential for treating cancer. Vor is focused on developing technologies that can enable selective targeting...
from Feb 2019
Board of Directors
234 Church St SUITE 1020, New Haven, CT 06510
Rallybio was established to identify and accelerate the development of transformative breakthrough therapies for patients with severe and rare disorders. The founders of the company – Martin...
from May 2018
Research Council Member
3400 Spruce St, Philadelphia, PA 19104
from Mar 2018
Board of Directors
645 Summer St SUITE 200, Boston, MA 02210
Akouos is developing targeted therapies to restore and preserve hearing in genetically-defined patient populations. Its founders include leaders in the fields of neurotology, inner ear drug ...
from Sep 2017
Board of Directors
50 Northern Ave, Boston, MA 02210
Entrada Therapeutics is a biotechnology company dedicated to transforming the treatment of devastating diseases through the intracellular delivery of biologics. www.entradatx.com
from Sep 2016
Founding Ceo, Chairman
Homology Medicines (NASDAQ: FIXX) is a genetic medicines company translating proprietary, cutting-edge gene editing and gene therapy technology into cures for patients with rare diseases. ww...
from Dec 2015
Member, Scientific Advisory Board
235 Kansas St, San Francisco, CA 94103
Grace Wilsey and other affected patients like her have two damaging mutations in their NGLY1 gene. Led by Grace's parents Matt and Kristen, an international team of clinicians and researcher...
from Jun 2014
Board of Directors
2400 District Ave SUITE 310, Burlington, MA
scPharmaceuticals (NASDAQ: SCPH) is developing a portfolio of transformative pharmaceutical products for subcutaneous delivery. The initial products are based on widely used generic drugs wh...
Mar 2014 — May 2018
Board of Directors
395 Winchester Ave, New Haven, CT 06511
Arvinas (NASDAQ: ARVN) is a pharmaceutical company focused on developing new small molecule strategies aimed at removing unwanted cellular proteins. We are translating these innovative prote...
from Jul 2013
Board of Directors
600 California St, San Francisco, CA 94108
Audentes (NASDAQ: BOLD) is a biotechnology company committed to the development and commercialization of innovative new treatments for people with life-threatening rare diseases through the ...
from Jul 2013
Board Observer and Acting Vp, Strategy and Corporate Development
3805 Old Easton Rd, Doylestown, PA 18902
Worked closely with scientific founding team during during first 18 months of Series A through recruitment of the CEO. Acquired by J&J in December 2015. Novira, founded by senior ex-Merck sc...
Aug 2012 — Dec 2015
Kauffman Fellow, Class 16
The Kauffman Fellows Program identifies, develops, and networks emerging global leaders in venture capital. Inspired by Ewing Marion Kauffman's legacy of promoting "economically independent ...
Jun 2011 — Jun 2013
Board Observer
South San Francisco, CA
Board Observer until IPO in March 2014 (NASDAQ: AKAO).
Achaogen is a clinical-stage company developing treatments for the problem of life-threatening, drug-resistant infections. www.achaog...
Nov 2010 — Mar 2014
Board Observer
555 Heritage Dr, Jupiter, FL 33458
Part of the lead team that drove and managed this investment ($8M Series A). It was acquired by Takeda in November 2012 for $140M. Envoy Therapeutics was a platform CNS drug discovery compan...
May 2010 — Nov 2012
Managing Partner
5AM Ventures is an early-stage venture capital firm focused on building next-generation life science companies. Founded in 2002, 5AM Ventures has over $685 million under management and is ac...
from 2010
Founder, President
Founded and ran an international development organization sponsoring infrastructure development (schools, clinics) for underserved communities in Eastern Mexico, while involving Princeton un...
Sep 2000 — Feb 2010
Education
2010 — 2010
2004 — 2008
2002 — 2010
2002 — 2010
1998 — 2002
Occupations
Executive
Managing Partner
Co-Founder
Chairperson
Health Specialist
Certified Nurse Aide
Partner
Chief Executive
Founder
Nurse
Nurse Practitioner
Skills
Venture Capital
Life Sciences
Drug Discovery
Strategy
Lifesciences
Pharmaceutical Industry
Entrepreneurship
Biotechnology
Corporate Development
Start Ups
Commercialization
Business Development
Oncology
Clinical Development
Cancer
Private Equity
Technology Transfer
Cell
FAQs about Kush M Parmar
What's the profession of Kush M Parmar?
This professional's job is Co-Founder
What are the profession of This expert?
These person's professions are Executive and Managing Partner
Where is Kush M Parmar located?
Kush M Parmar is located in Boston, Massachusetts.
What is Kush M Parmar's email?
Kush's email is ku**@5amventures.com and ku**@post.harvard.edu.
How many companies did Kush M Parmar work at?
Kush M Parmar worked at 19 jobs.
Where has Kush M Parmar studied?
Kush studied at the Harvard Business School from 2010 to 2010.
Are there any professional industries, that Kush M Parmar works in?
Kush M Parmar works in Venture Capital & Private Equity industry.
Are there any skills, that Kush M Parmar has?
Kush has such skills as Venture Capital, Life Sciences, Drug Discovery, Strategy, Lifesciences, Pharmaceutical Industry, Entrepreneurship, Biotechnology, and Corporate Development.